Benralizumab for the prevention of COPD exacerbations

Benralizumab for the prevention of COPD exacerbations

<p><h4>BACKGROUND</h4></p> <p>The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are n...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Criner, G, Celli, B, Brightling, C, Agusti, A, Papi, A, Singh, D, Sin, D, Vogelmeier, C, Sciurba, F, Bafadhel, M, Backer, V, Kato, M, Ramírez-Venegas, A, Wei, Y, Bjermer, L, Shih, V, Jison, M, O'Quinn, S, Makulova, N, Newbold, P, Goldman, M, Martin, U, Galathea and Terranova Study Investigators
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Massachusetts Medical Society 2019

Míreanna comhchosúla

Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies
de réir: Gerard J. Criner, et al.
Foilsithe / Cruthaithe: (2025-03-01)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
de réir: Singh D, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
de réir: O'Quinn S, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
de réir: George L, et al.
Foilsithe / Cruthaithe: (2019-06-01)

The use of benralizumab in the treatment of near fatal asthma: a new approach
de réir: Ramakrishnan, S, et al.
Foilsithe / Cruthaithe: (2020)

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
de réir: Brightling, C, et al.
Foilsithe / Cruthaithe: (2014)

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
de réir: Sriram Sridhar, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Exacerbations of chronic obstructive pulmonary disease: Time to rename
de réir: Bafadhel, M, et al.
Foilsithe / Cruthaithe: (2019)

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings
de réir: M. V. Zhuravleva, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Successful Introduction of Benralizumab for Eosinophilic Ascites
de réir: Nabil Belfeki, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Successful treatment of eosinophilic cystitis with benralizumab
de réir: W Donald Cooke, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
de réir: S. K. Zyryanov, et al.
Foilsithe / Cruthaithe: (2020-12-01)

New Perspectives on Chronic Obstructive Pulmonary Disease
de réir: Celli BR, et al.
Foilsithe / Cruthaithe: (2022-09-01)

Real-life cost-effectiveness of benralizumab in patients with severe asthma
de réir: A. Padilla-Galo, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
de réir: Ken Ohta, et al.
Foilsithe / Cruthaithe: (2018-04-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
de réir: Gómez-Bastero Fernández A, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Efficacy and use of benralizumab in patients with eosinophilic chronic rhinosinusitis
de réir: G.L. Fadda, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Benralizumab as initial treatment for chronic eosinophilic pneumonia
de réir: Shusuke Yazawa, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
de réir: Mirhojjat Khorasanizadeh, et al.
Foilsithe / Cruthaithe: (2017-07-01)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
de réir: Menzella F, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids
de réir: N. P. Kniajeskaia, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Response
de réir: Bafadhel, M, et al.
Foilsithe / Cruthaithe: (2011)

Response
de réir: Bafadhel, M, et al.
Foilsithe / Cruthaithe: (2011)

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
de réir: Alexandra M. Nanzer, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
de réir: Pelaia C, et al.
Foilsithe / Cruthaithe: (2018-03-01)

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
de réir: Eli Magen, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
de réir: Jocelyne Just, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
de réir: Stephen G. Noorduyn, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
de réir: Maria Blomberg, et al.
Foilsithe / Cruthaithe: (2020-11-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
de réir: Francesco Menzella, et al.
Foilsithe / Cruthaithe: (2016-12-01)

Response
de réir: Bafadhel, M, et al.
Foilsithe / Cruthaithe: (2011)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
de réir: FitzGerald JM, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma
de réir: S. V. Nedogoda, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
de réir: Moran, AM, et al.
Foilsithe / Cruthaithe: (2020)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
de réir: Kohei Somekawa, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
de réir: B Wang, et al.
Foilsithe / Cruthaithe: (2017-04-01)

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan
de réir: Nobuaki Kobayashi, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Comment on case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
de réir: Mustafa Ilker Inan, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
de réir: Erminia Ridolo, et al.
Foilsithe / Cruthaithe: (2020-10-01)

A case of paradoxical eosinophilic fasciitis in a patient on benralizumab
de réir: Michael J. Woodbury, BS, et al.
Foilsithe / Cruthaithe: (2023-10-01)